{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:57:39Z","timestamp":1791111459200,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s00223-008-9123-8","type":"journal-article","created":{"date-parts":[[2008,4,16]],"date-time":"2008-04-16T19:28:10Z","timestamp":1208374090000},"page":"258-262","source":"Crossref","is-referenced-by-count":22,"title":["The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients"],"prefix":"10.1007","volume":"82","author":[{"given":"Alessandro","family":"Gozzetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Merlotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Salvadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"De Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Avanzati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Franci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Marchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Stella","family":"Campagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranuccio","family":"Nuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lauria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,4,17]]},"reference":[{"key":"9123_CR1","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0022-2275(20)41388-4","volume":"33","author":"D Amin","year":"1992","unstructured":"Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657\u20131663","journal-title":"J Lipid Res"},{"key":"9123_CR2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/mol.61.5.1255","volume":"61","author":"PP Lehenkari","year":"2002","unstructured":"Lehenkari PP, Kellinsalmi M, Napankangas JP et\u00a0al (2002) Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP\/ATP translocase by a non-hydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255\u20131262","journal-title":"Mol Pharmacol"},{"key":"9123_CR3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","volume":"343","author":"JL Goldstein","year":"1990","unstructured":"Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425\u2013430","journal-title":"Nature"},{"key":"9123_CR4","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","volume":"9","author":"MJ Rogers","year":"2003","unstructured":"Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643\u20132658","journal-title":"Curr Pharm Des"},{"key":"9123_CR5","doi-asserted-by":"crossref","unstructured":"Russel RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanism of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int, Jan 24 [Epub ahead of print]","DOI":"10.1007\/s00198-007-0540-8"},{"key":"9123_CR6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","volume":"13","author":"SP Luckman","year":"1998","unstructured":"Luckman SP, Hughes De, Coxon FP et\u00a0al (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res 13:581\u2013589","journal-title":"J Bone Miner Res"},{"key":"9123_CR7","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","volume":"15","author":"FP Coxon","year":"2000","unstructured":"Coxon FP, Helfrich MH, Van\u2019t Hof R et\u00a0al (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467\u20131476","journal-title":"J Bone Miner Res"},{"key":"9123_CR8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","volume":"18","author":"PI Croucher","year":"2003","unstructured":"Croucher PI, De Hendrik R, Perry MJ et\u00a0al (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18:482\u2013492","journal-title":"J Bone Miner Res"},{"key":"9123_CR9","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1359\/jbmr.1999.14.12.2048","volume":"14","author":"S Derenne","year":"1999","unstructured":"Derenne S, Amiot M, Barille S et\u00a0al (1999) Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14:2048\u20132056","journal-title":"J Bone Miner Res"},{"key":"9123_CR10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","volume":"197","author":"HJ Gober","year":"2003","unstructured":"Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G (2003) Human T cell receptor cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197:163\u2013168","journal-title":"J Exp Med"},{"key":"9123_CR11","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood-2006-09-044321","volume":"110","author":"F Fiore","year":"2007","unstructured":"Fiore F, Castella B, Nuschak B et\u00a0al (2007) Enhanced ability of dendritic cells to stimulate innate and adaptative immunity on short-term incubation with zoledronic acid. Blood 110:921\u2013927","journal-title":"Blood"},{"key":"9123_CR12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1359\/jbmr.2000.15.3.599","volume":"15","author":"S Adami","year":"2000","unstructured":"Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E (2000) Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 15:599\u2013604","journal-title":"J Bone Miner Res"},{"key":"9123_CR13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S8756-3282(02)00924-9","volume":"32","author":"A Montagnani","year":"2003","unstructured":"Montagnani A, Gonnelli S, Cepollaro C, Campagna MS, Franci MB, Pacini S, Gennari C (2003) Changes in serum HDL and LDL cholesterol in patients with Paget\u2019s bone disease treated with pamidronate. Bone 32:15\u201319","journal-title":"Bone"},{"key":"9123_CR14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2407-6-60","volume":"6","author":"M Goffinet","year":"2006","unstructured":"Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaun C, Faye JC, Seronie-Vivien S (2006) Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 6:60","journal-title":"BMC Cancer"},{"key":"9123_CR15","first-page":"1720","volume":"91","author":"G Martini","year":"2006","unstructured":"Martini G, Gozzetti A, Salvadori S, Gennari L, Avanzati A, Franci B, Campagna M, Nuti R, Lauria F (2006) Zoledronic acid increases serum osteoprotegerin in early stage multiple myeloma. Haematol 91:1720\u20131721","journal-title":"Haematol"},{"key":"9123_CR16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedwald","year":"1972","unstructured":"Friedwald WT, Levy RI, Fredrickson DS (1972) Estimation of serum low density lipoprotein cholesterol without use of the preparative ultracentrifuge. Clin Chem 18:499\u2013502","journal-title":"Clin Chem"},{"key":"9123_CR17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/01.blo.0000129163.97988.06","volume":"422","author":"R Nuti","year":"2004","unstructured":"Nuti R, Martini G, Valenti R et\u00a0al (2004) Vitamin D status and bone turnover in women with acute hip fracture. Clin Orthop Relat Res 422:208\u2013213","journal-title":"Clin Orthop Relat Res"},{"key":"9123_CR18","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","volume":"81","author":"P Jones","year":"1998","unstructured":"Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVEs study). Am J Cardiol 81:582\u2013587","journal-title":"Am J Cardiol"},{"key":"9123_CR19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","volume":"92","author":"P Jones","year":"2003","unstructured":"Jones P, Davidson MH, Stein EA et\u00a0al (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across dose (STELLAR trial). Am J Cardiol 92:152\u2013160","journal-title":"Am J Cardiol"},{"key":"9123_CR20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clinbiochem.2007.03.016","volume":"40","author":"I Buhaescu","year":"2007","unstructured":"Buhaescu I, Izzedine H (2007) Mevalonate pathway: a review of clinical and therapeutical implications. Clin Bioch 40:575\u2013584","journal-title":"Clin Bioch"},{"key":"9123_CR21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0306-3623(01)00121-5","volume":"35","author":"R Ylitalo","year":"2002","unstructured":"Ylitalo R (2002) Bisphosphonates and atherosclerosis. Gen Pharmacol 35:287\u2013296","journal-title":"Gen Pharmacol"},{"key":"9123_CR22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1191\/0961203305lu2219oa","volume":"14","author":"M Bevilacqua","year":"2005","unstructured":"Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M (2005) Bisphosphonates and atherosclerosis: why? Lupus 14:773\u2013779","journal-title":"Lupus"},{"key":"9123_CR23","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/sj.ki.5001899","volume":"70","author":"V Persy","year":"2006","unstructured":"Persy V, De Broe M, Ketteler M (2006) Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 70:1537\u20131538","journal-title":"Kidney Int"},{"key":"9123_CR24","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et\u00a0al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"9123_CR25","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMc076132","volume":"356","author":"SR Cummings","year":"2007","unstructured":"Cummings SR, Schwartz AV, Black DM (2007) Alendronate and atrial fibrillation [letter]. N Engl J Med 356:1895\u20131896","journal-title":"N Engl J Med"},{"key":"9123_CR26","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS et\u00a0al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","journal-title":"N Engl J Med"},{"key":"9123_CR27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","volume":"139","author":"RE Hewitt","year":"2005","unstructured":"Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gammadelta T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139:101\u2013111","journal-title":"Clin Exp Immunol"},{"key":"9123_CR28","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1161\/01.CIR.0000103131.70301.4F","volume":"108","author":"RJ Aviles","year":"2003","unstructured":"Aviles RJ, Martin DO, Apperson-Hansen C et\u00a0al (2003) Inflammation as a risk factor for atrial fibrillation. Circulation 108:3006\u20133010","journal-title":"Circulation"},{"key":"9123_CR29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1006\/jmcc.2000.1147","volume":"32","author":"DR Wagoner Van","year":"2000","unstructured":"Van Wagoner DR, Nerbonne JM (2000) Molecular basis of electrical remodeling in atrial fibrillation. J Mol Cell Cardiol 32:1101\u20131117","journal-title":"J Mol Cell Cardiol"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-008-9123-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-008-9123-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-008-9123-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T08:38:07Z","timestamp":1631090287000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-008-9123-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["9123"],"URL":"https:\/\/doi.org\/10.1007\/s00223-008-9123-8","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}